Nosaka K and Matsuoka M

Adult T-cell leukemia-lymphoma as a viral disease: subtypes based on viral aspects.

ancer Sci ,112(5):1688-1694. doi: 10.1111/cas.14869. Epub 2021 Mar 30.

https://pubmed.ncbi.nlm.nih.gov/33630351/

Yasunaga JI.

Strategies of Human T-Cell Leukemia Virus Type 1 for Persistent Infection: Implications for Leukemogenesis of Adult T-Cell Leukemia-Lymphoma.

Front Microbiol 19;11:979,2020. 5.19 doi: 10.3389/fmicb.2020.00979.

https://pubmed.ncbi.nlm.nih.gov/32508789/

Oda K, Katonoda T, Hashiguchi Y, Kondo S, Narita Y, Iwamura K, Nosaka K, Jono H and Saito H.

Development and evaluation of a vancomycin dosing nomogram to achieve the target area under the concentration-time curve. A retrospective study.

J Infect Chemother 26(5):444-450,2020. doi: 10.1016/j.jiac.2019.11.009. Epub 2019 Dec 24.

https://pubmed.ncbi.nlm.nih.gov/31879186/

Oda K, Miyakawa T, Katanoda T, Hashiguchi Y, Iwamura K, Nosaka K, Yamaguchi A, Jono H and Saito H.

A case of recovery from aphasia following dose reduction of cefepime by bayesian prediction-based therapeutic drug monitoring.

J Infect Chemother 26(5):498-501,2020. doi: 10.1016/j.jiac.2019.10.006. Epub 2020 Mar 4.

https://pubmed.ncbi.nlm.nih.gov/32143960/

Maeda M, Tanabe-Shibuya J, Miyazato P, Masutani H, Yasunaga JI, Usami K, Shimizu A, Matsuoka M.

IL-2/IL-2 Receptor Pathway Plays a Crucial Role in the Growth and Malignant Transformation of HTLV-1-Infected T Cells to Develop Adult T-Cell Leukemia.

Front Microbiol. 2020 Mar 6;11:356. doi: 10.3389/fmicb.2020.00356. eCollection 2020.

https://pubmed.ncbi.nlm.nih.gov/32210945/

Fuji S, Kurosawa S, Inamoto Y, Murata T, Utsunomiya A, Uchimaru K, Yamasaki S, Inoue Y, Moriuchi Y, Choi I, Ogata M, Hidaka M, Yamaguchi T, Fukuda T.

A decision analysis comparing unrelated bone marrow transplantation and cord blood transplantation in patients with aggressive adult T-cell leukemia-lymphoma.

Int J Hematol 111(3):427-433,2020. doi: 10.1007/s12185-019-02777-w. Epub 2019 Nov 7.

https://pubmed.ncbi.nlm.nih.gov/31701480/

Shichijo T, Fuji S, Nagler A, Bazarbachi A, Mohty M, Savani BN.

Personalizing rabbit anti-thymocyte globulin therapy for prevention of graft-versus-host disease after allogeneic hematopoietic cell transplantation: is there an optimal dose?

Bone Marrow Transplant 55(3): 505-522,2020.doi: 10.1038/s41409-019-0643-9. Epub 2019 Aug 21.

https://pubmed.ncbi.nlm.nih.gov/31435032/

Cui G, Shimba A, Ma G, Takahara K, Tani-Ichi S, Zhu Y, Asahi T, Abe A, Miyachi H, Kitano S, Hara T, Yasunaga JI, Suwanai H, Yamada H, Matsuoka M, Ueki K, Yoshikai Y, Ikuta K.

IL-7R-Dependent Phosphatidylinositol 3-Kinase Competes with the STAT5 Signal to Modulate T Cell Development and Homeostasis.

J Immunol. 2020 Feb 15;204(4):844-857. doi: 10.4049/jimmunol.1900456. Epub 2020 Jan 10.

https://pubmed.ncbi.nlm.nih.gov/31924648/

Nishimura N, Endo S, Kawano Y.

Myeloma Mouse Models in Studying Myeloma Associated Bone Disease.

Encyclopedia of Bone Biology 3:355-361,2020.

Nagafuji K, Matsumura I, Shimose T, Kawaguchi T, Kuroda J, Nakamae H, Miyamoto T, Kadowaki N, Ishikawa J, Imamura Y, Yamazaki H, Akashi K, Kanakura Y.

Cessation of nilotinib in patients with chronic myelogenous leukemia who have maintained deep molecular responses for 2 years: a multicenter phase 2 trial, stop nilotinib (NILSt).

Shirayama R, Takedani H, Chikasawa Y, Ishiguro A, Ishimura M, Isobe K, Uchiba M, Ogata Y, Kakuda H, Kusuhara K, Shirahata A.

Perioperative safety and haematostatic efficacy of a new bypassing agent pd-FVIIa/FX (Byclot) in haemophilia patients with high-responding type inhibitors.

Ishikawa M, Iriyama N, Tokuhira M, Takaku T, Sato E, Sugimoto K J, Nakazato T, Fujita H, Kimura Y, Fujioka I, Komatsu N, Asou N, Kizaki M, Hatta Y, Kawaguchi T.

Potential role for secondgeneration tyrosine kinase inhibitors in patients with chronic myeloid leukemia harboring additional clonal chromosome abnormalities: A retrospective CML Cooperative Study Group analysis.

Takenaka K, Minami T, Yoshihashi Y, Hirata S, Kimura Y, Kono H.

Decrease in MPO-ANCA after administration of benralizumab in eosinophilic granulomatosis with polyangiitis.

Nishimura N, Radwan MO, Amano M, Endo S, Fujii E, Hayashi H, Ueno S, Ueno N, Tatetsu H, Hata H, Okamoto Y, Otsuka M, Mitsuya H, Matsuoka M, Okuno Y.

Novel p97/VCP inhibitor induces endoplasmic reticulum stress and apoptosis in both bortezomib-sensitive and -resistant multiple myeloma cells.

Cancer Sci. 2019 Oct;110(10):3275-3287. doi: 10.1111/cas.14154. Epub 2019 Aug 14. PMID: 31368616; PMCID: PMC6778635.

https://pubmed.ncbi.nlm.nih.gov/31368616/

Onitsuka K, Tokuda R, Kuwata-Higashi N, Kumamoto H, Aoki M, Amano M, Kohgo S, Das D, Haraguchi K, Mitsuya H, Imoto S.

Synthesis and evaluation of the anti-hepatitis B virus activity of 4′-Azido-thymidine analogs and 4′-Azido-2′-deoxy-5-methylcytidine analogs: structural insights for the development of a novel anti-HBV agent.

Nucleosides Nucleotides Nucleic Acids. 2019 Sep 12;1-12. doi: 10.1080/15257770.2019.1664749. [Epub ahead of print]. PMID: 31514570.

https://pubmed.ncbi.nlm.nih.gov/31514570/

Noyori O, Komohara Y, Nasser H, Hiyoshi M, Ma C, Pan C, Carreras J, Nakamura N, Sato A, Ando K, Okuno Y, Nosaka K, Matsuoka M, and Suzu S.

Expression of IL-34 correlates with macrophage infiltration and prognosis of diffuse large B-cell lymphoma.

Clin Transl Immunology.2019 Aug 13;8(8):e1074. doi: 10.1002/cti2.1074. eCollection 2019. PMID: 31417675

https://pubmed.ncbi.nlm.nih.gov/31417675/

Iriyama N, Tokuhira M, Sato E, Sugimoto K J, Takaku T, Ishikawa M, Nakazato T, Fujita H, Kimura Y, Fujioka I, Asou N, Komatsu N, Kizaki M, Hatta Y, Kawaguchi T.

Smoking influences the outcomes of patients receiving tyrosine kinase inhibitors for chronic myeloid leukemia in the chronic phase: A retrospective analysis.

Ma G, Yasunaga JI, Ohshima K, Matsumoto T, and Matsuoka M.

Pentosan polysulfate demonstrates anti-HTLV-1 activities in vitro and in vivo.

J Virol 93:e00413-19, 2019.

https://pubmed.ncbi.nlm.nih.gov/31167921/

Takamatsu Y, Aoki M, Bulut H, Das D, Amano M, Sheri VR, Kovari LC, Hayashi H, Delino NS, Ghosh AK, Mitsuya H.

Novel Protease Inhibitors Containing C-5-Modified bis-Tetrahydrofuranylurethane and Aminobenzothiazole as P2 and P2′ Ligands That Exert Potent Antiviral Activity against Highly Multidrug-Resistant HIV-1 with a High Genetic Barrier against the Emergence of Drug Resistance.

Antimicrob Agents Chemother. 2019 Jul 25;63(8):e00372-19. doi: 10.1128/AAC.00372-19. PMID: 31085520; PMCID: PMC6658756.

https://pubmed.ncbi.nlm.nih.gov/31085520/

Amano M, Bulut H, Tamiya S, Nakamura T, Koh Y, Mitsuya H.

Amino-acid inserts of HIV-1 capsid (CA) induce CA degradation and abrogate viral infectivity: Insights for the dynamics and mechanisms of HIV-1 CA decomposition.

Sci Rep. 2019 Jul 8;9(1):9806. doi: 10.1038/s41598-019-46082-2. PMID: 31285456; PMCID: PMC6614453.

https://pubmed.ncbi.nlm.nih.gov/31285456/

Amano M, Salcedo-Gómez PM, Yedidi RS, Zhao R, Hayashi H, Hasegawa K, Nakamura T, Martyr CD, Ghosh AK, Mitsuya H.

Novel Central Nervous System (CNS)-Targeting Protease Inhibitors for Drug-Resistant HIV Infection and HIV-Associated CNS Complications.

Antimicrob Agents Chemother. 2019 Jun 24;63(7):e00466-19. doi: 10.1128/AAC.00466-19. PMID: 31061155; PMCID: PMC6591644.

https://pubmed.ncbi.nlm.nih.gov/31061155/

Murata S, Mushino T, Hosoi H, Kuriyama K, Nishikawa A, Nagakura S, Horikawa K, Yonemura Y, Nakakuma H, Sonoki T, Hanaoka N.

Soluble NKG2D ligands are potential biomarkers and sentinels of  immune-mediated bone marrow injury in bone marrow failure syndromes.

Matsumura T, Nakamura-Ishizu A, Takaoka K, Maki H, Muddineni SSNA, Wang CQ, Suzushima H, Kawakita M, Asou N, Matsuoka M, Kurokawa M, Osato M, and Suda T.

TUBB1 dysfunction in inherited thrombocytopenia causes genome instability.